Evidence map›Paper›PMID 23945567›Full record

ArticleJournal of lipid research2013

Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid.

Nathaniel W Snyder, Sonia D Revello, Xiaojing Liu, Suhong Zhang, Ian A Blair

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Lipoxin AbioRxiv : the preprint server for biology · 2024
    Article
  2. Article
  3. Article
  4. ATP-binding cassette proteins BCRP, MRP1 and P-gp expression and localization in the human umbilical cord.Xenobiotica; the fate of foreign compounds in biological systems · 2016
    Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nathaniel W SnyderCenters for Cancer Pharmacology and Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA.
Sonia D Revello
Xiaojing Liu
Suhong Zhang
Ian A Blair
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM008076 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A · 1985 to 2023
$10.8M
Development of Breast Cancer Risk Model Based on Estrogen MetabolomicsR01CA158328 · NCI · UNIVERSITY OF VIRGINIA · PI BLAIR, IAN ALEXANDER, HEITJAN, DANIEL FRANCIS · 2012 to 2013
$779k
NCI NIH HHS R01 CA158328NCI NIH HHS R01-CA-158328NIEHS NIH HHS P30 ES013508NIEHS NIH HHS P30-ES-013508NIGMS NIH HHS T32 GM008076NIGMS NIH HHS T32-GM-008076
6 · The paper itself

Abstract

Cyclooxygenases (COX) metabolize arachidonic acid (AA) to hydroxyeicosatetraenoic acids (HETE), which can then be oxidized by dehydrogenases, such as 15-hydroxyprostaglandin dehydrogenase (15-PGDH), to oxo-eicosatetraenoic acids (ETE). We have previously established that 11-oxo-eicosatetraenoic acid (oxo-ETE) and 15-oxo-ETE are COX-2/15-PGDH-derived metabolites. Stable isotope dilution (SID) chiral liquid chromatography coupled with electron capture atmospheric pressure chemical ionization (ECAPCI) single reaction monitoring (SRM) MS has been used to quantify uptake of 11-oxo-ETE and 15-oxo-ETE in both LoVo cells and human umbilical vein endothelial cells (HUVEC). Intracellular 11-oxo- and 15-oxo-ETE concentrations reached maximum levels within 1 h and declined rapidly, with significant quantitative differences in uptake between the LoVo cells and the HUVECs. Maximal intracellular concentrations of 11-oxo-ETE were 0.02 ng/4 × 10⁵ cells in the LoVo cells and 0.58 ng/4 × 10⁵ cells in the HUVECs. Conversely, maximal levels of 15-oxo-ETE were 0.21 ng/4 × 10⁵ in the LoVo cells and 0.01 ng/4 × 10⁵ in the HUVECs. The methyl esters of both 11-oxo- and 15-oxo-ETE increased the intracellular concentrations of the corresponding free oxo-ETEs by 3- to 8-fold. 11-oxo-ETE, 15-oxo-ETE, and their methyl esters inhibited proliferation in both HUVECs and LoVo cells at concentrations of 2-10 μM, with 11-oxo-ETE methyl ester being the most potent inhibitor. Cotreatment with probenecid, an inhibitor of multiple drug resistance transporters (MRP)1 and 4, increased the antiproliferative effect of 11-oxo-ETE methyl ester in LoVo cells and increased the intracellular concentration of 11-oxo-ETE from 0.05 ng/4 × 10⁵ cells to 0.18 ng/4 × 10⁵ cells. Therefore, this study has established that the COX-2/15-PGDH-derived eicosanoids 11-oxo- and 15-oxo-ETE enter target cells, that they inhibit cellular proliferation, and that their inhibitory effects are modulated by MRP exporters.

Indexed as

Arachidonic AcidsATP-Binding Cassette, Sub-Family C ProteinsBiological TransportCell Line, TumorCell ProliferationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansHuman Umbilical Vein Endothelial CellsIntracellular Space11-oxoeicosatetraenoic acidABCC4 protein, humanArachidonic AcidsATP-Binding Cassette, Sub-Family C Proteinsmultidrug resistance-associated protein 1cancercyclooxygenaseeicosanoidsexporters

Identifiers

PMID23945567
PMCPMC3793611
OpenAlexW2122225847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.